A detailed history of Versant Capital Management, Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 692 shares of BEAM stock, worth $16,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares
692
Previous 497 39.24%
Holding current value
$16,220
Previous $12,000 41.67%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 02, 2025

BUY
$21.55 - $30.35 $4,202 - $5,918
195 Added 39.24%
692 $17,000
Q3 2024

Oct 07, 2024

BUY
$22.57 - $33.14 $9,772 - $14,349
433 Added 676.56%
497 $12,000
Q2 2024

Jul 05, 2024

BUY
$21.22 - $32.66 $1,358 - $2,090
64 New
64 $1,000
Q3 2023

Oct 11, 2023

SELL
$23.01 - $32.46 $2,254 - $3,181
-98 Reduced 93.33%
7 $0
Q2 2023

Jul 10, 2023

BUY
$29.32 - $35.99 $3,078 - $3,778
105 New
105 $3,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.65B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.